OREANDA-NEWS The French pharmaceutical manufacturer Sanofi cannot fully fulfill its obligations under the Special investment contract (SPIC). Due to logistical problems, the company almost stopped exporting insulin from the Russian plant to the European Union, and this was one of the important conditions for obtaining tax preferences under the SPIC. Lawyers consider the most likely scenario to be a change in the terms of the contract by agreement of the parties.

Sanofi in 2022-2023 practically did not ship insulin produced at the company's plant in the Orel region abroad, the last major deliveries were in 2021 to Germany, where 2 million packages were sent, RNC Pharma calculated for Kommersant. Yuri Mochalin, Director of Corporate Relations at Sanofi, told Kommersant that additional volumes of the drug were supplied to Germany. According to him, now the Oryol plant "Sanofi Vostok", taking into account "the logistical features of the last two years and the current situation," has focused on supplies to the domestic market.